Please assess the completion status of the following clinical trial:

Trial Title: Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Met the 1987 ACR Revised Criteria for RA~2. A history of inadequate response to infliximab or adalimumab in combination with methotrexate.~3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.~Exclusion Criteria:~1. ACR functional class IV~2. Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab.~3. Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects who are mAb ADA positive
- Group B (Type: EXPERIMENTAL): Subjects who are mAb ADA negative
- Group C (Type: PLACEBO_COMPARATOR): Subjects who are mAb ADA positive
- Group D (Type: PLACEBO_COMPARATOR): Subjects who are mAb ADA negative

Based on this trial design, predict the completion outcome and termination type (if applicable).